I’m leading Santen Pharmaceutical's global supply chain pharmaceutical and medical device serialization and traceability, and responsible for the digital strategy. Before joining Santen, I worked as a Principal Advisor for Epista Life Science, helping life science companies with pharma digitalization strategic advisory and initiatives. The customer assignments ranged from digitalization strategies to implementing global regulatory compliance in manufacturing IT, and medicine serialization and traceability. Prior to this, I worked as Senior Consultant and Advisor for NNE, Novo Nordisk engineering and consulting company, in Global Pharma Consulting and Finished Pharma Products departments. The customer references are available upon request.I served as Chief Executive Officer at Original1 GmbH (a joint venture of SAP, Nokia and Giesecke&Devrient - leaders in enterprise IT, mobile and security) servicing a cloud and mobile platform for product serialization, traceability and consumer authentication services in Europe and China. In Europe, Original1 focused in serialization and traceability services for pharmaceutical, consumer products and manufacturing industries. In China, Original1 commercialized the first drug traceability and authentication cloud and mobile service for pharmaceutical companies and consumers utilizing China FDA Drug Monitoring Service.Prior to Original1 I headed Nokia Authentication Solution business in Nokia China empowering consumers and businesses to authenticate product originality and counterfeits using their mobile phones. The products covered consumer products, drugs and ID cards and ultimately the solution was selected as the best anti-counterfeit solution in China by China RFID Journal and China Anti-counterfeit Association.I also mentor and support early stage biotech and medical device startups with funding and strategic planning. In this capacity, I'm co-founder and strategic advisor for the board of Rokote Laboratories, the only adenovirus vectored intranasal Covid vaccine developer in Europe. I'm also co-founder of Pandemblock, the developer of novel antibody mimetic antiviral intranasal inhibitors for prevention of infections and transmissions of pandemic pathogens such as SARS and influenza.